Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA’s Inspection Volume Projected To Return To Normal Levels In FY 2022 As Backlog Looms

Executive Summary

Additional hiring in FDA’s FY 2022 budget request also is expected to help address the inspections delayed by the coronavirus pandemic.

You may also be interested in...



US FDA Gets Less FY2022 Funding From Senate Than House, Different Inspection Priorities

CDER would receive $17m less in Senate appropriations bill compared to House veion, while CFSAN's total would be nearly $10m less. Overall,  Senate bill includes around $50.4m less in funding for FDA than House bill.

FDA Would Get Less Funding, Different Inspection Priorities Under Senate Legislation Than House

CDER would lose the most money in the Senate appropriations bill compared to the House version, while CBER would see an increase.

US FDA’s In-Person Foreign Inspections Remain On House Appropriators’ Minds

The House Appropriations Committee also does not want the agency to become too dependent on alternative inspection tools.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144413

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel